News about "chemotherapy "

First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC

The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.

Chemotherapy | 14/01/2026 | By News Bureau |  107

Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer

Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.

Chemotherapy | 12/01/2026 | By News Bureau

Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer

Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.

Chemotherapy | 08/01/2026 | By News Bureau |  151

China Updates Ivonescimab Label After NSCLC Survival Gains

China’s drug regulator has approved a label update for Akeso’s ivonescimab, citing Phase III data showing significant improvements in progression-free and overall survival in EGFR-TKI-resistant non-small cell lung cancer patients.<br />

Chemotherapy | 07/01/2026 | By News Bureau |  259

Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies

Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.

Chemotherapy | 27/08/2025 | By Dineshwori |  190

Amgen Reports Positive Interim Results for IMDELLTRA in Small Cell Lung Cancer Study

IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.

Chemotherapy | 14/04/2025 | By Abha |  453

Akeso Gets NMPA Approval of Penpulimab for Nasopharyngeal Cancer

With this new approval, penpulimab now provides comprehensive treatment coverage across all stages of NPC, offering patients a continuous immunotherapy option from first-line to third-line therapy.

Chemotherapy | 17/03/2025 | By Aishwarya |  428

AstraZeneca India Secures CDSCO Approval for Durvalumab

AstraZeneca Pharma India has been granted permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO).

Chemotherapy | 27/09/2024 | By Aishwarya |  457

Astellas Gets EU Approval for VYLOY in Combination with Chemotherapy

Astellas Pharma Inc. has announced that the European Commission (EC) has approved VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy.

Chemotherapy | 23/09/2024 | By Aishwarya |  657

AstraZeneca Completes Acquisition of Fusion

AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).

Chemotherapy | 06/06/2024 | By Aishwarya |  360